Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) EBITDA (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed EBITDA for 16 consecutive years, with $4.1 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 42.54% to $4.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.3 million through Dec 2025, up 110.7% year-over-year, with the annual reading at $16.3 million for FY2025, 110.7% up from the prior year.
  • EBITDA for Q4 2025 was $4.1 million at Niagen Bioscience, down from $4.2 million in the prior quarter.
  • The five-year high for EBITDA was $7.1 million in Q4 2024, with the low at -$8.8 million in Q3 2021.
  • Average EBITDA over 5 years is -$1.4 million, with a median of -$1.3 million recorded in 2022.
  • The sharpest move saw EBITDA tumbled 110.7% in 2021, then surged 4332.74% in 2024.
  • Over 5 years, EBITDA stood at -$5.3 million in 2021, then soared by 72.84% to -$1.4 million in 2022, then skyrocketed by 88.37% to -$168000.0 in 2023, then soared by 4332.74% to $7.1 million in 2024, then crashed by 42.54% to $4.1 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $4.1 million, $4.2 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.